BD Boston
Date: Location: Cost:
September 4, 2018 Hilton Boston Back Bay
40 Dalton Street
Boston, MA 02115

Starting at $1950


Dress Code:
Business Attire



Biotech Buyouts in 2018: M&A Market Activity

Defining your BD Strategy vs. Opportunism - Consistent Corporate Vision

The Future of Financing Models: Alternative Capital Sources

Raising Capital to Optimize Value Creation

Small Biotech Deal-Making and Partnering: Lessons to Be Learned

Carving up the Pie: Creative Deal Structures

Life After the Deal: Strategies for Alliance Management

When to Think Commercial

Partnering: How New Modalities Impact Deal Making

BD & Academic Partnerships: New Models for Mutually Beneficial Collaborations

Growth Options: Partner, Grow, Exceed

Partnerships in Rare Disease

The Role of Long Term Alliances in Drug Development Strategy

The Future of Deal-Making & Partnerships: 2018 & Beyond




Time Agenda
7:00-8:00 am

Registration and Networking Breakfast

8:00-8:15 am

Welcome and Opening Remarks
Chris ViehbacherManaging Partner, Gurnet Point Capital; Paris Panayiotopoulosformer CEO, ARIAD; Julie KampfCEO, JBK Associates; David MollerSVP, BD, Emerging Technology & Innovation, Eli Lilly

8:15-8:45 am

The New Start Up: Working with Life Science Venture Capital and Biotech Incubators 
Michal PremingerExecutive Director, Harvard University; Joshua ResnickPartner, SV Life Sciences; Ramani VaranasiPresident & CEO, X-Biotix Therapeutics; Rebecca YuHead, JLabs Toronto, Johnson & Johnson Innovation
Moderator: David MollerSVP, BD, Emerging Technology & Innovation, Eli Lilly

8:45-9:15 am

Gaining Momentum: From Start Up to Public 
Richard Brudnick, EVP, BD & Alliance Management, Bioverativ, Inc.; Elan EzicksonCOO & Head, Corporate Development, Scholar Rock; Hans HullCBO, Pliant Therapeutics; Micah MackisonVP, Corporate Development & Strategy, Assembly Biosciences; Sanuj RavindranCBO, aTyr Pharma
Moderator: Julie KampfCEO, JBK Associates

9:15-9:45 am

Impact of Pricing and Reimbursement on Deal Making
Steven BloomSVP Corporate Development, Verastem; Melissa Bradford KlugCBO, Keryx Biopharmaceuticals; Christian MazziCCO, Managing Director, Established Brands, Mundipharma; Todd SmithCEO, Novum Pharma
Moderator: Julie LocklearHead, HEOR, EMD Serono

9:45-10:05 am

Fireside Chat
Bob OliverPresident & CEO, Otsuka America; Chris ViehbacherManaging Partner, Gurnet Point Capital
Moderator: Christoph WestphalCo-Founder & Partner, Longwood Fund

10:05-10:30 am

Networking Break

10:30-11:00 am

Growth Options: Partner, Grow, Exceed
John CelebiCOO, X4 Pharmaceuticals; Luc DochezCEO, Tusk Therapeutics; Jeb KeiperCBO, Nimbus Therapeutics; Anna MaroneyHead, Alliance Management, AbbVie; Mark NuttallHead, MS & Immunology BD, Sanofi Genzyme 
Moderator: David BarrowHead, Life Sciences, L.E.K. Consulting

11:00-11:30 am

Partnering with Cell & Gene Therapy Companies
David GiljohannCEO, Exicure; Deborah PalestrantHead, BD, Editas Medicine; Joe PaynePresident & CEO, Arcturus; Robin SmithCEO, ORIG3N
Moderator: Donna Armentano, Executive Director, Global Head Gene Therapy, for External R&D Innovation (ERDI), Worldwide R&D, Pfizer

11:30-12:00 pm

Creative Deal Structures
Ken ArakiHead, Corporate Development, Global BD, Takeda; Hugh Cole, CBO, ARIAD; Drew FromkinCEO, Tarveda Therapeutics; Jeremy GrunsteinExecutive Director, BD, Amgen; Shakti NarayanVP, Head, Transactions, Johnson & Johnson
Moderator: Doug GiordanoSVP, Worldwide BD, Pfizer

12:00-12:50 pm

Networking Lunch

12:50-1:20 pm

Building a Robust Pipeline: Where are Tomorrow's Drugs Coming From?
Todd KruegerPresident, AOBiome; Ken LebiodaSVP, Business & Corporate Development, Resverlogix; Torsten Mummenbrauer, SVP, BD, Hookipa Biotech  AG; Cynthia SchwalmPresident, North America Commercial Operations, IPSEN
Moderator: Rosamond DeeganCBO, Bicycle Therapeutics

1:20-1:50 pm

When to Think Commercial 
Susan GrafCBO, Epizyme; Bob SilvermanHead, Externalized Drug Discovery Partnering, Roche; Catherine SohnChairman, ConcentRx
Moderator: Robert BeardsleyCOO, Galera Therapeutics

1:50-2:20 pm

Bubble Reactions: Public & Private Perspectives
Nouhad Husseini, VP, BD, Regeneron Pharmaceuticals; Peng LeongCBO, Novogen; Chris SeatonSenior VP, Negotiations, Bayer; Sergio TraversaCEO, Relmada Therapeutics
Moderator: Adam GridleyPresident & CEO, Histogenics

2:20-2:50 pm

Placing the Patient at the Center of the Business Model
Slava AkmaevSVP, Chief Analytics Officer, Co-Founder, BERG; Todd BazemoreCOO, Santhera Pharmaceuticals; Jean-Sebastien CleiftieCBO, Erytech Pharma; Maria GoutsouHead, Ecosystem Engagement, UCB
Moderator: Kate Haviland, CBO, Blueprint Medicines

2:50-3:15 pm

Networking Break

3:15-3:45 pm

Life After the Deal: Strategies for Alliance Management
Walter OgierCEO, Regenacy Pharmaceuticals; Henry RathVP, Business Development, Seres Therapeutics; Brianne WeingartenHead, LBD Alliance Management, Purdue Pharma L.P.
Moderator: James ZanewiczCBO, R&D, Tulane University School of Medicine

3:45-4:15 pm

Managing Shareholder Expectations while Focusing on Growth
Zandy ForbesPresident & CEO, MeiraGTx; Anna KazanchyanChairman, CEO, Saghmos Therapeutics; Patrick Tricoli, CEO, Nanobiotix US
Moderator: Stephen PotterCBO, AGTC

4:15-4:45 pm

Which Sectors are Hot, Which Sectors are Not?
Yasir Al-WakeelCFO & Head of Corporate Development, Merrimack Pharmaceuticals; Robert BagdorfVP, Worldwide BD, Pfizer; Kia MoteshareiHead, Global Licensing & BD, Neurology & Immunology, EMD Serono; Georges RawadiVP Business Development & IP, Celyad
Moderator: Jonathan LewisCEO, Samus Therapeutics

4:45-5:15 pm

The Future of Deal-Making & Partnerships: 2017 and Beyond
Mike CrowleyGlobal Head, Innovation Partnering, Roche; Philippe Lopes-FernandesSVP; Global Head, BD & Alliance Management, EMD Serono; Ivana Magovcevic-LiebischSVP; Head, Global BD, Teva; Jigar RaythataCBO, Jounce Therapeutics
Moderator: Sanjiv PatelEVP, Chief Strategy Officer, Allergan

5:15-5:25 pm

Presentation of the Deal of the Year Award

5:25-6:30 pm

Cocktails and Hors d'oeuvres

Supporting Sponsors: (see all sponsors)